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Abstract
Introduction: The 19q12 locus is amplified in a subgroup of oestrogen receptor (ER)-negative grade III breast
cancers. This amplicon comprises nine genes, including cyclin E1 (CCNE1), which has been proposed as its ‘driver’.
The aim of this study was to identify the genes within the 19q12 amplicon whose expression is required for the
survival of cancer cells harbouring their amplification.
Methods: We investigated the presence of 19q12 amplification in a series of 313 frozen primary breast cancers
and 56 breast cancer cell lines using microarray comparative genomic hybridisation (aCGH). The nine genes
mapping to the smallest region of amplification on 19q12 were silenced using RNA interference in phenotypically
matched breast cancer cell lines with (MDA-MB-157 and HCC1569) and without (Hs578T, MCF7, MDA-MB-231,
ZR75.1, JIMT1 and BT474) amplification of this locus. Genes whose silencing was selectively lethal in amplified cells
were taken forward for further validation. The effects of cyclin-dependent kinase 2 (CDK2) silencing and chemical
inhibition were tested in cancer cells with and without CCNE1 amplification.
Results: 19q12 amplification was identified in 7.8% of ER-negative grade III breast cancer. Of the nine genes
mapping to this amplicon, UQCRFS1, POP4, PLEKHF1, C19ORF12, CCNE1 and C19ORF2 were significantly over-
expressed when amplified in primary breast cancers and/or breast cancer cell lines. Silencing of POP4, PLEKHF1,
CCNE1 and TSZH3 selectively reduced cell viability in cancer cells harbouring their amplification. Cancer cells with
CCNE1 amplification were shown to be dependent on CDK2 expression and kinase activity for their survival.
Conclusions: The 19q12 amplicon may harbour more than a single ‘driver’, given that expression of POP4, PLEKHF1,
CCNE1 and TSZH3 is required for the survival of cancer cells displaying their amplification. The observation that
cancer cells harbouring CCNE1 gene amplification are sensitive to CDK2 inhibitors provides a rationale for the testing
of these chemical inhibitors in a subgroup of patients with ER-negative grade III breast cancers.
Introduction
Breast cancer is a heterogeneous disease encompassing a
number of distinct entities, characterised by distinct bio-
logical features and clinical behaviour. Recent evidence
has suggested that this heterogeneity is underpinned by
distinct patterns of genomic aberrations, which may
contribute to the different transcriptomic profiles and
clinical phenotypes [1-4]. Importantly, it has been
shown that oestrogen receptor (ER)-positive and
-negative breast cancers are fundamentally different dis-
eases, with distinct transcriptomic profiles, gene copy
number aberrations and somatic structural rearrange-
ments [5-8].
Based on the concept of oncogene addiction, we [9,10]
and others [11,12] have demonstrated that the constella-
tion of genes that are consistently overexpressed when
amplified is enriched for genes selectively required for
the survival of cancer cells harbouring their amplifica-
tion and can be exploited as potential therapeutic tar-
gets. Using a combination of microarray-based
comparative genomic hybridisation (aCGH) and gene
expression profiling [11-19], previous studies have
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identified genes which are consistently overexpressed
when amplified and suggested potential “amplicon dri-
vers” (for example, FGFR1, FGFR2, GAB2, PPAPDC1B
and ZNF703). It should be noted, however, that whilst
many potential targets have been postulated, critical
molecular drivers of several amplicons remain elusive.
It has now become evident that not all genes within
an amplicon are overexpressed when amplified. For
example, in the HER2 amplicon, only 7 of the 13 genes
that map to the smallest region of amplification are
expressed at significantly higher levels when amplified
[20-22]. Conversely, evidence now suggests that an
amplicon may harbour more than one driver
[10,11,17,18,23,24]. For instance, within the 8p11.2
amplicon, the expression of FGFR1, PPAPDC1B,
WHSC1L1, LSM1 and ZNF103 has been shown to be
selectively required for the survival of cancer cells har-
bouring the amplification of these genes
[10,11,17-19,25].
Amplification of the 19q12 locus has been reported to
be found in up to 15% of ER-negative breast cancers
[9,26]. This amplicon often encompasses the cell cycle
regulatory gene CCNE1, which has been shown to be
overexpressed in a subgroup of ER-negative cancers.
Although mRNA and protein expression are more pre-
valent than gene amplification, CCNE1 has been postu-
lated as the driver gene of this amplicon [9,26-28].
There is evidence, however, that genes within this
amplicon other than CCNE1 are consistently overex-
pressed when amplified [29], including POP4 and
C19ORF2.
The aims of this study were (i) to characterise the
19q12 amplicon in breast cancer, (ii) to determine the
genes that are overexpressed when amplified in this
amplicon, (iii) to investigate which of the genes mapping
to this amplicon are selectively required for the survival
of cells harbouring their amplification, and (iv) to deter-
mine if cancer cells with CCNE1 gene amplification are




Fresh/frozen primary invasive breast carcinomas from
313 patients were retrieved from independent consecu-
tive cohorts after approval by local Research Ethic Com-
mittees from the authors’ institutions. None of the
patients received pre-operative chemotherapy and/or
endocrine therapy. Tumours were either micro-dissected
to ensure a tumour cell content > 75% as previously
described [9], or one representative section of each
tumour was stained with haematoxylin & eosin and only
samples with > 70% of neoplastic cells were included, as
previously described [19]. A description of the cohort
analysed here is presented in Additional file 1 Table S1.
Out of the samples included in this study, the aCGH
profiles of 95, 24 and 8 cases were previously reported
in Natrajan et al. [9], Turner et al. [19], and Hunger-
mann et al. [30], respectively. The remaining samples
comprise a series of 31 consecutive HER2-positive
breast cancers retrieved from the tissue bank of The
Netherlands Cancer Institute (NKI), and a collection of
119 consecutive breast cancers from the tissue bank of
the NKI. RNA was available for 48 cases and the gene
expression profiles were reported in Natrajan et al. [29].
RNA of sufficient quantity and quality was available for
48 cases and the gene expression profiles were reported
in Natrajan et al. [29]. Immunohistochemistry for ER,
progesterone receptor (PR) and HER2 was performed as
previously described [9,31]. Histological grade was deter-
mined by two pathologists (FCG and JSR-F) using the
modified Scarff-Bloom-Richardson system [32]. ER and
PR status was determined by immunohistochemical ana-
lysis using the 6F11 (1:150) and PgR636 (1:200) antibo-
dies, respectively, as previously described [33]. The
Allred scoring system was employed and tumours were
considered positive when the score was ≥ 3. HER2 gene
amplification was defined based on chromogenic in situ
hybridisation analysis using a US Food and Drug
Administrator approved probe (SpotLight HER2 amplifi-
cation probe, Invitrogen, Carlsbad, CA, USA) and/or by
inspection of the results of aCGH analysis, as previously
described [20]. Tumours were classified into ER-posi-
tive/HER2-negative, ER-negative/HER2-negative and
HER2-positive subgroups, given i) the results of recent
studies demonstrating that the transcriptomic profiles of
ER-positive/HER2-negative, ER-negative/HER2-negative
and HER2-positive tumours are fundamentally different
[34,35], ii) the technical issues related to the assignment
of tumour profiled with different platforms into the
‘intrinsic’ molecular subtypes [36,37], and iii) that these
subgroups are currently employed to define the systemic
therapy for patients with breast cancer.
RNA and DNA extraction
DNA and RNA were extracted as previously described
[29]. DNA concentration was measured with Picogreen®
(Invitrogen, Paisley, UK) according to the manufac-
turer’s instructions, and RNA was quantified using the
Agilent 2100 Bioanalyser with RNA Nano LabChip Kits
(Agilent Biosystems, Stockport, UK).
Cell lines
Fifty-six breast cancer cell lines were obtained from
ATCC (LGC Standards, Teddington, UK) unless other-
wise specified (Additional file 2 Table S2), maintained as
previously described [16,19,38] and subjected to aCGH
analysis as described below. Out of these cell lines,
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MDA-MB-157, HCC1569, MDA-MB-231, Hs578T,
MCF7, ZR75.1, BT474 and JIMT1 were used as models
for the functional characterisation of the 19q12
amplicon.
Microarray-based comparative genomic hybridisation
(aCGH)
The 32K bacterial artificial chromosome (BAC) re-array
collection (CHORI) tiling path aCGH platform was con-
structed at the Breakthrough Breast Cancer Research
Centre, as described previously [33,39]. This type of
BAC array platform has been shown to be as robust as,
and to have comparable resolution with, high density
oligonucleotide arrays [40-42]. DNA labelling, array
hybridisations and image acquisition were performed as
previously described [9]. aCGH data were pre-processed
and analysed using an in-house R script (BACE.R) in R
version 2.13.0, as previously described [29,33]. In brief,
raw Log2 ratios of intensity between samples and pooled
female genomic DNA were read without background
subtraction and normalised in the LIMMA package in R
using PrinTipLoess. Outliers were removed based upon
their deviation from neighbouring genomic probes using
an estimation of the genome-wide median absolute
deviation of all probes. After filtering polymorphic BACs
a final dataset of 31,367 clones with unambiguous map-
ping information according to the February 2009 build
(hg19) of the human genome [43]. Log2 ratios were
rescaled using the genome-wide median absolute devia-
tion in each sample, and then smoothed using circular
binary segmentation in the DNACopy package as pre-
viously described [29,33]. Loss was defined as a circular
binary segmentation (cbs)-smoothed Log2 ratio < -0.08.
Low-level gain was defined as a cbs-smoothed Log2
ratio in the range 0.08 to 0.45, corresponding to
approximately three to five copies of the locus, whilst
gene amplification was defined as having a Log2 ratio >
0.45, corresponding to more than five copies [9,33,39].
Threshold values were determined as previously
described [9] and validated empirically by means of in
situ hybridisation methods in previous publications
[9,33,39,44-46]. A categorical analysis was applied to the
BACs after classifying them as representing amplifica-
tion (>0.45), gain (>0.08 and ≤ 0.045), loss (< -0.08), or
no-change according to their cbs-smoothed Log2 ratio
values [29,33]. Threshold values were determined and
validated as previously described [9]. aCGH data, the
analysis history, script and code are publically available
online at [47].
FISH validation of aCGH results
Fluorescence in situ hybridisation (FISH) analysis for
19q12 amplification was carried out as previously
described [9,48]. Briefly, a FISH probe mapping to 30.10
to 30.25 Mb on chromosome 19 was generated using
the BAC RP11-372I05 and biotin labelled as previously
described [48]. Pre-treatment and hybridisation were
carried out as previously described [9,48]. Cases were
considered amplified if > 50% of neoplastic cells har-
boured large signal clusters or > 5 signals/nucleus. FISH
performed with observers blinded to the results of
aCGH analysis (Additional file 3 Figure S1).
TP53 mutation analysis
The entire coding sequence of the TP53 gene (exons 2
to 11) was sequenced as previously described [39,49].
PCR amplification and Sanger sequencing was carried
out in the 16 cases with 19q12 amplification using 5 ng
of tumour DNA [50] using the DNA Sequencing Kit
BigDye Terminator v 3.1 Cycle Sequencing Ready Reac-
tion Mix (Applied Biosystems, Warrington, UK), as
described [39]. Sequences were analysed with Mutation
Surveyor software (Softgenetics, State College, PA,
USA).
Gene expression analysis
Gene expression profiling of breast cancer samples in
the ‘Natrajan’ dataset was performed using the Illu-
mina human WG6 version 2 expression array as pre-
viously described [29]. Raw gene expression values
were robust-spline normalised using the Bioconductor
lumi package in R (R Foundation, Vienna, Austria)
Genes were mapped to their genomic location using
the lumiHumanAllv2 annotation database available
from Bioconductor. Only Illumina transcript probes
with detection P-values < 0.01 in > 25% of samples
were included; this resulted in a dataset of 12,699 tran-
scriptionally regulated probes with accurate and
unequivocal mapping information. Gene-expression
data are publicly available at ArrayExpress (accession
number: E-TABM-543 [51]. The final dataset com-
prises 48 cases, whose clinicopathological characteris-
tics are fully described elsewhere [29].
Identification of genes whose expression correlates with
copy number changes
To identify genes whose expression levels correlate with
copy number changes, cbs-smoothed Log2 ratios from
aCGH data were used to assign the aCGH states for
each of the genes in the gene expression dataset using
the median values for all BACs that overlap with the
genomic position of each gene. This resulted in a 1:1
matrix of expression values and aCGH cbs values, which
were used for downstream statistical analysis. To define
genes that were overexpressed when amplified, a Mann-
Whitney U test was performed using categorical aCGH
states (that is, amplification versus no amplification) as
the grouping variable and the expression of genes as the
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dependent variable, as previously described [16,29]. P-
values < 0.05 were considered significant.
Short interfering RNA (siRNA)-mediated silencing
Nine genes that mapped to the smallest region of ampli-
fication on 19q12 were selected for functional evalua-
tion, namely CCNE1, UQCRFS1, POP4, PLEKHF1,
C19ORF2, C19ORF12, VSTM2B, ZNF536, TSHZ3. Each
gene was targeted with four distinct siRNAs (siGEN-
OME SMARTpool) obtained from Thermo Scientific
(Epsom, UK): siCCNE1 - pool M-003213-02;
siUQCRFS1 - pool M-020100-01; siPOP4 - pool M-
020046-00; siPLEKHF1 - pool M-018423-01; siC19ORF2
- pool M-017399-01; siC19ORF12 - pool M-014731-01;
siVSTM2B - pool M-023625-01; siZNF536 - pool M-
020506-01; siTSHZ3 - pool M-014119-01; and siCDK2 -
pool M-003236-04. siGENOME Non-Targeting siRNA
Pool #1 and #2 (siCON, D-001206-13 and D-001206-14)
were used as controls. As a positive control (that is, a
gene whose silencing is lethal) we employed siRNA
pools for PLK1 (M-003290-01) as previously described
[44]. To identify conditions that maximise transfection
efficiency and minimise lipid-mediated toxic effects,
multiple transfection conditions for each cell line were
tested. Lipofectamine RNAiMax (Invitrogen, Paisley,
UK) and Dharmafect 4 (Thermo Scientific, Epsom, UK)
were identified as the most efficient and least toxic for
the cell lines studied. Breast cancer cells were trans-
fected with target and control siRNAs (50 nmol/L per
well in 100 μL total volume) in 96-well plates, according
to the manufacturers’ instructions as previously
described [44,52]. A total of 1,000 to 5,000 cells were
seeded per well that yielded 80 to 90% confluency in the
controls at 10 days. Media were replaced every two days
and cell viability was assessed using the CellTiter-Glo®
assay (Promega, Southampton, UK) as previously
described [44]. The average cell survival fraction for
each siRNA was calculated relative to that of cells trans-
fected with non-coding control siRNA.
Drug sensitivity assays
For assessment of drug sensitivity, cell lines were plated
and transfected with target or control siRNAs in 96-well
plates. At 48 hours post transfection, media were sup-
plemented with serial dilutions (10-4M to 10-9M) of
doxorubicin, cisplatin, paclitaxel, or the CDK1, CDK2
and CDK9 inhibitor AZD5438 (Tocris Biosciences, Bris-
tol, UK), essentially as previously described [44]. All
experiments were performed in triplicate. Survival was
assessed with CellTiter-Glo® cell viability assay after
seven days of drug treatment and survival fraction com-
pared to siRNA vehicle treated cells. Survival curves and
estimated SF50 (the drug concentration used following
which 50% of cells survive) were calculated using non-
linear regression with GraphPad Prism V5.0 (La Jolla,
CA, USA).
Cell cycle analysis
FACS analysis for cell cycle assessment was performed
with Propidium Iodide staining five days after transfec-
tion as described previously [52].
Western blotting
Total protein lysates (40 μg) from treated and untreated
cells were separated by SDS-PAGE according to stan-
dard protocols, and immunoblotting was carried out
using primary antibodies directed against CCNE1 (HE-
12, Abcam ab3927, Cambridge, UK), CDK2 (2546, Cell
Signaling Technology, Danvers, MA, USA), phospho-
CDK2 (2561, Cell Signaling), PLEKHF1 (20389-1-AP,
Proteintech, Chicago, IL, USA), POP4 (Rpp29, sc-23048,
Santa Cruz Biotechnology, Santa Cruz, CA, USA),
TSHZ3 (sc-134132, Santa Cruz), and CCNB1 (4135, Cell
Signaling), and against b-tubulin as loading control
(5346, Cell Signaling). Protein expression levels after
siRNA silencing were assessed by western blotting 72
hours after transfection of the cells and protein bands
quantified using ImageJ 1.44p software (NIH, Bethesda,
MD, USA) [53].
Real-time quantitative reverse transcriptase PCR (qRT-
PCR)
First strand synthesis was performed as previously
described [9], and qRT-PCR was performed using Taq-
Man chemistry on the ABI Prism 7900HT (Applied Bio-
systems), using the standard curve method. Assays for
CCNE1, PLEKHF1, UQCRFS1, C19ORF12, C19ORF2,
VSTM2B, ZNF536, TSHZ3, TFRC and MRPL19 were
purchased from Applied Biosystems. Expression levels
were normalised to those of TFRC and MRPL19 (Assay






CDK2, Hs99999188_m1-CCNB1). For the assessment of
RNA levels after gene silencing, RNA was extracted using
Trizol (Invitrogen, Paisley, UK), and transcript levels
were assessed 48 hours after transfection. The level of
siRNA silencing was measured relative to that of cells
transfected with non-coding control siRNA.
Statistical analysis
All statistical analysis was performed with R version
2.13.0 or GraphPad Prism version 5.0. All statistical
tests performed adopted 95% confidence intervals. A
two-tailed P-value of < 0.05 was considered significant.
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Results
19q12 amplification is associated with grade III ER-
negative breast cancers
To determine the clinicopathological correlates of the
19q amplification, 313 frozen breast cancers were sub-
jected to aCGH analysis [9]. Amplification at 19q12
(27.8 to 32.9 Mb) was found in 16/313 (5.1%) of all
tumours, and 7.8% (16/188) of grade III cancers (Figure
1A-C; Table 1). Amplification of 19q12 was significantly
associated with histological grade III (Fisher’s exact test
P = 0.018, Table 1), lack of ER expression (Fisher’s exact
test, P = 0.0042) and ER-negative/HER2-negative sub-
type (Chi-square test P = 0.0056, Table 1). Given the
small number of samples in the subgroup analysis of the
clinical subtypes, we have compared the prevalence of
19q12 amplification in ER-negative/HER2-negative vs
the other subtypes using the Fisher’s exact test, which
confirmed a significance association between 19q12
amplification and ER-negative/HER2-negative breast
cancers (P = 0.0024).
Amplification of the 19q12 locus was shown to be
complex and this amplicon displayed multiple core
regions recurrently amplified in primary breast cancers
(Figure 1C). Within these cores, nine genes were identi-
fied, including CCNE1 (Table 2). Although CCNE1 has
been proposed as a driver of this amplicon in breast
cancer [14,26], CCNE1 was amplified in only 5 out of
the 16 primary breast cancers harbouring amplification
of the 19q12 locus (Figure 1C).
Potential 19q12 amplicon drivers
Genes within an amplicon that are overexpressed when
amplified have been shown to constitute potential
amplicon drivers and therapeutic targets
[9-12,17-19,29,54]. To determine which of the amplified
genes in the 19q12 amplicon were significantly overex-
pressed when amplified, aCGH and microarray expres-
sion data from 48 microdissected grade III breast
cancers were interrogated [29,36]. This analysis revealed
that out of all the genes mapping to the 19q12 amplifi-
cation with detectable gene expression, UQCRFS1,
POP4, PLEKHF1, C19ORF12, CCNE1 and C19ORF2 had
expression levels that significantly correlated with gene
copy number (Pearson’s correlation r value = 0.65, 0.77,
0.44, 0.63, 0.66, 0.81, respectively; all P < 0.05) and
UQCRFS1, POP4, C19ORF12, CCNE1 and C19ORF2
were significantly overexpressed when amplified (Mann-
Whitney U test P < 0.05) (Figure 1D, Table 2). VSTM2B
expression was undetected in any of the tumours
analysed.
To identify models for the study of the genes overex-
pressed when amplified in the 19q12 amplicon, we first
subjected 56 breast cancer cell lines to aCGH analysis
and identified two cell lines (that is, HCC1569 and
MDA-MB-157), which harbour amplification of 19q12
(minimal amplified region from 29.17 to 32.82 Mb). In a
way akin to the majority of primary breast cancers har-
bouring 19q12 amplification [9], the only cell lines har-
bouring amplification of this locus were ER-negative/
HER2-negative (MDA-MB-157) or ER-negative/HER2-
positive (HCC1569) [16,38]. A panel of phenotypically
matched (in terms of ER, PR and HER2 expression)
breast cancer cell lines were selected and used as con-
trols (that is, MDA-MB-231, Hs578T, MCF7, ZR75.1,
JIMT1 and BT474; Additional file 2 Table S2). Quantita-
tive RT-PCR of cDNA from cancer cells harbouring
19q12 amplification or lacking amplification of this
locus revealed that UQCRFS1, POP4, CCNE1 and
C19ORF2 genes were overexpressed when amplified (P
< 0.05, Mann Whitney U test, Figure 1E), whereas
VSTM2B, ZNF536 and TSHZ3 expression could not be
detected in the majority of cell lines at the mRNA level.
Taken together, our results suggest that UQCRFS1,
POP4, C19ORF12, CCNE1 and C19ORF2 are overex-
pressed in primary breast cancers and/or breast cancer
cell lines harbouring their amplification, and may consti-
tute potential drivers of this amplicon.
CCNE1, POP4, PLEKHF1 and TSHZ3 are selectively
required in cells harbouring their amplification
There are several lines of evidence to suggest that one
of the characteristics of amplicon drivers is that their
expression is selectively required for the survival of can-
cer cells harbouring their amplification [9-12,19]. Given
the complexity of amplification at this locus, we chose
to assess the potential amplicon drivers by siRNA silen-
cing of all genes mapping to the 19q12 amplicon (that
is, UQCRFS1, VSTM2B, POP4, C19ORF12, PLEKHF1,
CCNE1, C19ORF2, ZNF536 and TSHZ3) regardless of
their expression levels. Silencing of CCNE1, PLEKHF1,
POP4, ZNF536 and TSHZ3 expression selectively
reduced cell viability in cancer cells harbouring 19q12
gene amplification but had a significantly lower impact
on the survival of breast cancer cells lacking amplifica-
tion of this locus (t-test P < 0.05; Figure 2). Upon
siRNA pool deconvolution, the observation that silen-
cing of CCNE1, PLEKHF1, POP4 and TSHZ3 is selec-
tively lethal in cancer cells harbouring their
amplification was validated (that is, two or more indivi-
dual siRNAs were selectively lethal in cancer cells har-
bouring amplification of the gene silenced; Figure 3A).
siRNA silencing of these genes was confirmed at the
mRNA and protein levels (Figures 3B, C).
Assessment of the protein levels of POP4, PLEKHF1,
CCNE1 and TSHZ3 was performed in the cell lines
used in this study. Expression levels of POP4, PLEKHF1
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Figure 1 Patterns of 19q12 amplification and mRNA expression of genes mapping to the 19q12 amplicon. (A) aCGH heatmap of
chromosome 19q12 in 313 primary breast cancers. Tumours were ordered according to histological grade, oestrogen receptor (ER) status and
19q amplification status. (B) Chromosome 19 ideogram and aCGH plots illustrating the patterns of 19q12 amplification (bright green, amp), copy
number gain (green, gain) and no copy number change (black, no change) in primary breast cancers. (C) aCGH heatmap of region of
amplification in 16 breast cancers harbouring amplification of the 19q12 locus. CCNE1 (box) was amplified in 5/16 cancers. (D) Heatmaps
depicting aCGH states (left) and gene expression values (middle) in 48 primary breast cancers with or without 19q12 amplification. Genes are
ordered according to their chromosomal position and tumours grouped according to the 19q12 amplification status. Bar plots (right) depict the
Mann-Whitney U test results for the comparison of gene expression as a continuous variable and gene amplification as the grouping variable. In
red, genes with P-values < 0.05 (dotted line). (E) aCGH heatmap of the 19q12 amplicon in breast cancer cells with (MDA-MB-157, HCC1569) or
without (MDA-MB-231, Hs578T, MCF7, ZR75.1, BT474, JIMT1) 19q12 amplification. Box-and-whiskers plots showing the expression of genes within
the amplified region in cell lines with (red) and without (grey) 19q12 amplification. *: genes significantly overexpressed when amplified (Mann-
Whitney U test, P < 0.05). In all aCGH heatmaps (A, C, D, E), green: copy number loss, black: no copy number change; pink: copy number gain;
bright red: gene amplification. In the microarray gene expression heatmap (D), green: down-regulation; red: up-regulation.
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and CCNE1 were significantly higher in cancer cells har-
bouring amplification of the genes encoding these pro-
teins than in cancer cells devoid of amplification of
these loci (Figure 4, Mann-Whitney U test P < 0.05). No
significant association between TSHZ3 gene amplifica-
tion and protein expression was observed, even when
corrected for proliferation levels, as defined by CCNB1
expression levels (data not shown).
To test whether silencing of these genes affects cell
cycle in cancer cells with or without 19q12 amplifica-
tion, DNA content was measured upon gene silencing.
Upon PLEKHF1, POP4 or TSHZ3 siRNA-mediated gene










Whole cohort 16 (5.1%) 297 (94.9%) NA 5 (1.6%) 308 (98.4%) NA
Histological grade* 0.0018+ 0.1693+
I/II 0 (0%) 109 (100%) 0 (0%) 109 (100%)
III 16 (8%) 188 (92%) 5 (2%) 199 (98%)
ER 0.0042+ 0.01984+
Positive 3 (2%) 166 (98%) 0 (0%) 169 (100%)
Negative 13 (9%) 131 (91%) 5 (3.5%) 139 (96.5%)
HER2 0.5398+ 0.9801+
Positive 2 (3%) 62 (97%) 1(1.6%) 63(98.4%)
Negative 14 (6%) 235 (94%) 4(1.6%) 245(98.4%)
Subtypes 0.0056**^ 0.0500**^
ER-/HER2- 11 (11%) 90 (89%) 0.0024*** 4 (4%) 97 (96%) 0.0399***
HER2 2 (3%) 62 (97%) 1 (2%) 63 (98%)
ER+/HER2- 3 (2%) 145 (98%) 0 (0%) 148 (100%)
Amp, amplified; CCNE1, cyclin E1; ER, oestrogen receptor; NA, not applicable; Not amp, not amplified.
*Histological grade determined by the modified Scarff-Bloom-Richardson system [32].
Significant P-values are highlighted in bold.
+: Fisher’s exact test
**: Chi-square test
***: Comparison between ER-/HER2- vs the remaining subtypes by Fisher’s exact test.
^: Given that > 20% of the groups have n < 5, the Chi-square P-value should be interpreted with caution.















VSTM2B V-set and transmembrane domain containing 2B 30,017 to
30,055
NA NA





PLEKHF1 pleckstrin homology domain containing, family F (with




C19ORF12 Uncharacterised protein C19ORF12 30,190 to
30,206
0.63* 0.0018
CCNE1 Cyclin E1 30,303 to
30,315
0.66* 0.0071
C19ORF2 RPB5-mediating protein 30,433 to
30,507
0.81* 0.0001
ZNF536 Zinc finger protein 536 30,863 to
31,049
-0.03 0.6064
TSHZ3 Teashirt zinc finger homeobox 3 31,766 to
31,840
0.08 0.5426
Position refers to the genomic location from the Ensembl genome browser based on the February 2009 hg19 build of the genome
• P < 0.05; significant P-values are highlighted in bold; MWU (Mann-Whitney U test).
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silencing, slight but not statistically significant increases
in the subG1 fraction and decreases in the G2/M frac-
tion were observed in cancer cells with (that is, MDA-
MB-157 and HCC1569) or without (that is, MDA-MB-
231, JIMT1, ZR75.1 and BT474) 19q12 amplification
(Additional file 4 Figure S2). These observations suggest
that the silencing of these genes does not significantly
alter the cell cycle profile. On the other hand, in cancer
cells harbouring 19q12 amplification, CCNE1 silencing
resulted in a significant decrease in the fraction of cells
in S/G2 and increase in the proportion of cells in G1
and subG1 cell cycle phases (P < 0.0001, Chi-square
test, Figure 5A).
To assess whether amplification and overexpression of
CCNE1, PLEKHF1, POP4 and TSHZ3 would alter the
response of breast cancer cells to common chemothera-
peutic agents, we subjected cancer cells with or without
19q12 gene amplification to treatment with doxorubicin,
cisplatin and paclitaxel upon silencing of these genes.
No significant difference in the sensitivity of these cells
to the chemotherapy agents tested was observed upon
silencing of PLEKHF1, POP4 or TSHZ3 compared to
non-targeting siRNAs (data not shown). CCNE1 siRNA-
mediated silencing, however, was found to reduce the
sensitivity of cancer cells to doxorubicin, cisplatin and
paclitaxel in cancer cells harbouring 19q12 amplification
cells but not in cancer cells lacking amplification of this
locus (Additional file 5 Figure S3). This is not surpris-
ing, given that these chemotherapy agents target cycling
cells and, here, we demonstrate that CCNE1 siRNA-
mediated silencing leads to G1 arrest.
CDK2 silencing and chemical inhibition is selectively
lethal in cancer cells harbouring CCNE1 gene
amplification
Given that i) cancer cells harbouring CCNE1 gene
amplification depend on CCNE1 expression for their
survival, ii) that one of the main functions of CCNE1 is
to activate CDK2 in the transition from G1/S phase
[55], and iii) that CCNE1 RNAi-mediated silencing led
to G1 arrest, we posited that cancer cells harbouring
CCNE1 gene amplification would be dependent on
Figure 2 Impact of RNA interference silencing of genes mapping to the 19q12 amplicon on cell viability. Bar plots of the survival
fraction relative to non-targeting siRNA control of breast cancer cells with (red) or without (black) 19q12 amplification upon transfection with
short interfering RNA (siRNA) SMARTpools targeting UQCRFS1, VSTM2B, POP4, PLEKHF1, C19ORF12, CCNE1, C19ORF2, ZNF536 and TSHZ3. Cell
viability was assessed after 10 days with CellTiter-Glo® cell viability assay. P-values of t-test of the survival fraction between cancer cells
harbouring the amplification of the gene tested and those lacking its amplification (P < 0.05 was considered significant). Error bars represent the
standard error of the mean of three replicates.
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Figure 3 PLEKHF1, POP4 and TSHZ3 expression is selectively required for the survival of 19q12-amplified breast cancer cells. (A)
Barplots illustrating the survival fractions of cancer cells with (red) or without (black) 19q12 amplification upon transfection with short interfering
RNA (siRNA) targeting POP4, PLEKHF1, UQCRFS1, CCNE1, ZNF536, and TSHZ3 relative to siRNA controls (siCON) of individual duplex
oligonucleotides (1 to 4). Error bars represent the standard error of the mean of three replicates. Reduced cell viability effects were considered
validated if at least two individual oligonucleotides caused a significantly higher loss of viability of cancer cells harbouring 19q12 amplification
than in those lacking amplification of this locus (* depicts significant t-test P-values for the comparison of the survival fraction between cells with
and without amplification of the target gene for an individual oligonucleotide). siZNF536 failed to validate with two or more individual siRNA
oligonucleotides. (B) Effects on target mRNA expression after silencing of PLEKHF1, POP4, TSHZ3 and CCNE1 with individual oligonucelotides in
MDA-MB-157 cells as determined by quantitative RT-PCR. (C) Effects on target protein expression after silencing of PLEKHF1, POP4, TSHZ3 and
CCNE1 with Dharmacon individual oligonucelotides and smartpool (SP) in MDA-MB-157 (CCNE1) and MCF7 cells (PLEKHF1, POP4, and TSHZ3) as















































Figure 4 PLEKHF1, POP4, and CCNE1 are overexpressed when amplified at the protein level. (A) Western blot analysis of cell line panel
with antibodies against POP4, PLEKHF1, CCNE1 and TSHZ3 in the breast cancer cell lines studied. In red, breast cancer cell lines harbouring
amplification of the 19q12 locus. (B) Bar plots depicting POP4, PLEKHF1, CCNE1 and TSHZ3 protein expression quantified relative to the b-
tubulin loading control, using ImageJ 1.44p (NIH, USA).
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CDK2 expression and kinase activity for their survival.
siRNA-mediated CDK2 silencing resulted in a signifi-
cantly higher reduction in cell survival of cancer cells
harbouring CCNE1 gene amplification than in cancer
cells devoid of amplification of this gene (t-test, P <
0.05, Figures 5B, C). Furthermore, cancer cells harbour-
ing CCNE1 gene amplification displayed a higher sensi-
tivity to the CDK1, CDK2 and CDK9 small molecule
inhibitor AZD5438 [56,57] than cancer cells lacking
CCNE1 gene amplification (t-test, P = 0.019, Figure 5D).
Moreover, primary breast cancers harbouring CCNE1
amplification were found to have higher levels of CDK2
mRNA expression, adjusted for proliferation using the
mRNA levels of CCNB1 [58], than breast cancers devoid
of CCNE1 amplification (P = 0.02789, t-test, data not
shown).
Taken together, these data provide evidence that
tumours harbouring 19q12 amplification have more
than one ‘driver’ and suggest that cancer cells with
CCNE1 amplification depend on CDK2 expression and
kinase activity for their survival.
Discussion
Here we demonstrate that the 19q12 locus is amplified
in 5.1% of all invasive breast cancers and that this
amplification is preferentially found in grade III ER-
negative breast cancers. This is consistent with previous
observations that suggested that 19q12 amplification is
found in 5 to 15% of breast cancers and is associated
with ER-negative disease [9,26,27,29]. Furthermore,
through a combination of genomic profiling of primary
breast cancers and breast cancer cell lines and RNAi
experiments, we have demonstrated that the 19q12
amplicon may contain more than one ‘driver’.
Previous studies have suggested that CCNE1 is the
likeliest driver of the 19q12 amplicon [26,27]. Although
our results support the contention that CCNE1 is one of
the drivers of this amplicon, in this study CCNE1 was
amplified only in 5 out of 16 breast cancers harbouring
19q12 amplification. These observations are in agree-
ment with those from studies of the 19q12 amplicon in
gastric cancer, where CCNE1 was amplified only in a









































Figure 5 Cancer cells harbouring CCNE1 gene amplification show increased sensitivity to CDK2 silencing and chemical inhibition. (A)
The fraction of cells in each phase of the cell cycle are shown following transfection with CCNE1 short interfering RNA (siRNA) and control
(siCON) in cell lines with (HCC1569 and MDA-MB-157) and without (MDA-MB-231, ZR75.1, BT474 and JIMT1) CCNE1 amplification. (B) Bar plots
illustrating the survival fraction of cells following transfection with CDK2 siRNA using individual duplex oligonucelotides (1 to 4) and a
SMARTpool (SP) in cancer cells harbouring (red) or lacking (black) 19q12 amplification. Error bars represent the standard error of the mean of
three replicates. Survival fractions are shown relative to those of siCON transfected cells. (* depicts significant t-test P values for the comparison
of the survival fraction between cells with and without amplification of the target gene for an individual oligonucleotide). (C) Effects on CDK2
protein expression of CDK2 siRNA silencing with Dharmacon individual oligonucelotides and SMARTpool (SP) in MDA-MB-157 cells. (D) Dose
response curves of breast cancer cell lines with (red) or without (black) 19q12 amplification to the CDK1, CDK2, and CDK9 inhibitor ADZ5438.
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with those of previous studies that have found a preva-
lence of CCNE1 amplification in 1.2% to 1.4% of pri-
mary breast cancers [14,60]. Taken together, these lines
of evidence suggest that CCNE1 may not be the sole
driver of this amplicon and that other genes within the
19q12 amplicon may also constitute drivers. Consistent
with this hypothesis, we observed that cancer cells har-
bouring 19q12 amplification require the expression of
not only CCNE1, but also PLEKHF1, POP4 and TSHZ3
for their survival.
PLEKHF1 (pleckstrin homology domain containing,
family F (with FYVE domain) member 1) encodes a pro-
tein that is known to induce apoptosis through the lyso-
somal-mitochondrial pathway and triggers caspase-
independent apoptosis [61]. Recent evidence suggests
that this process involves the recruitment of phosphory-
lated p53 and that silencing of endogenous p53 impairs
its function [62]. Despite its reported role in apoptosis,
PLEKHF1 siRNA-mediated silencing in cancer cells har-
bouring its amplification did not lead to an increase in
the sub-G0 proportion of cells. It could be speculated
that in a TP53 mutant background (as was the case of
HCC1569 and MDA-MB-157; Additional file 2 Table
S2), PLEKHF1 gene amplification and overexpression
may confer a selective advantage through mechanisms
other than through the recruitment of phosphorylated
p53. Regrettably, no breast cancer cell lines harbouring
PLEKHF1 gene amplification and wild-type TP53 were
available to test this hypothesis. All primary breast can-
cers with PLEKHF1 amplification, however, were found
to harbour TP53 mutations, suggesting that PLEKHF1
amplification and TP53 gene mutations may have epi-
static interactions and that TP53 mutational status
should be taken into account in the evaluation of the
potential role of PLEKHF1 as a therapeutic target. POP4
(processing of precursor 4, ribonuclease P/MRP subunit
(S. cerevisiae)) encodes one of the protein subunits of
the small nucleolar ribonucleoprotein complexes and is
involved in the processing of precursor RNAs. Further
studies investigating the mechanisms that lead to a sur-
vival advantage in cancer cells harbouring amplification
and overexpression of PLEKHF1 and POP4 are war-
ranted. TSHZ3 (teashirt zinc finger homeobox 3) is a
zinc finger transcription factor and has been shown to
be involved in muscle cell differentiation [63,64]. Given
that the TSHZ3 gene promoter is reported to be fre-
quently methylated in primary breast cancers and breast
cancer cell lines [65], this gene has been suggested to
display tumour suppressor function. Our results do not
corroborate this hypothesis and suggest that THSZ3 is
one of the drivers of the 19q12 amplicon, given that we
demonstrate here that THSZ3 is amplified in 2.6% of
breast cancers, and that its silencing is selectively lethal
in cancer cells harbouring its amplification. Although
protein expression is not directly correlated with ampli-
fication, the breast cancer cell lines harbouring 19q12
amplification displayed either the highest levels of
THSZ3 protein expression (that is, MDA-MB-157) or
the presence of a THSZ3 isoform (HCC1569, Figure 4).
Although CCNE1 amplification was restricted to a
subset of cancers harbouring 19q12 amplification, we
set out to investigate if breast cancer cells harbouring
CCNE1 amplification would be selectively dependent on
the expression of this gene for their survival. siRNA-
mediated silencing of CCNE1 had a significantly greater
effect on the survival of cancer cells harbouring CCNE1
amplification than in those lacking its amplification.
This is in agreement with a recent study in ovarian can-
cer that demonstrated that reduction of CCNE1 expres-
sion significantly inhibited cell growth in CCNE1
expressing cells, with a more profound effect in ovarian
cancer cells harbouring CCNE1 gene amplification [66].
Moreover, forced expression of CCNE1 in cells with low
expression has been previously shown to result in
increased cell proliferation [66]. Here we demonstrate
that CCNE1 siRNA silencing in breast cancer cells har-
bouring CCNE1 gene amplification, but not in those
lacking this amplification, resulted in a significant arrest
in G1 (Figure 5 and Additional file 4 Figure S2). These
findings provide a rationale for the apparent selective
reduction in sensitivity to chemotherapy agents caused
by CCNE1 siRNA silencing reported in ovarian cancer
cells harbouring CCNE1 gene amplification [67], and
described here in breast cancer cells harbouring CCNE1
gene amplification (Additional file 5 Figure S3).
Progression through the G1/S phase of the cell cycle is
regulated through the partnership of CDK2 with its reg-
ulatory subunit CCNE1 [55]. Given that CCNE1 silen-
cing in cancer cells harbouring CCNE1 gene
amplification leads to G1 arrest, we tested whether
these cells would be dependent on CDK2 expression
and kinase activity for their survival. CDK2 siRNA silen-
cing and inhibition of CDK2 kinase activity using a
CDK1, CDK2 and CDK9 inhibitor (AZD5438) resulted
in significantly higher reduction in survival of cancer
cells harbouring CCNE1 gene amplification. This is in
agreement with a recent study based on the analysis of
the conditional mouse models MMTV-Low Molecular
Weight (LMW)-Ccne1; Tp53+/-; Cdk2+/+, MMTV-
LMW-Ccne1; Tp53+/-; Cdk2+/- and MMTV-LMW-
Ccne1; Tp53+/-; Cdk2-/-. While mice with at least one
functional copy of Cdk2 consistently developed mam-
mary gland tumours, Cdk2-/- mice did not develop
tumours through 24 months. Furthermore, administra-
tion of two Cdk inhibitors delayed the progression of
mammary gland tumours in MMTV-LMW-Ccne1; Tp53
+/-; Cdk2+/+ mice [68]. It should be noted that although
MCF7 cells showed a similar sensitivity to the CDK1,
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CDK2 and CKD9 inhibitor AZD5438, CDK2 siRNA
silencing had a significantly more limited impact on
the viability of these cells, suggesting that the sensitiv-
ity of MCF7 cells to AZD5438 is unlikely to be caused
by inhibition of CDK2. Taken together, these results
demonstrate that breast cancer cells harbouring
CCNE1 gene amplification are dependent on CDK2
expression and kinase activity for their survival and
suggest that CCNE1 amplification may constitute a
potential biomarker of sensitivity to CDK2 inhibitors.
It should be noted, however, that CDK1, CDK2 and
CDK9 inhibitors may also be efficacious in a subgroup
of ER-positive breast cancers, given that MCF7 cells
also show sensitivity to AZD5438. Analysis of the
results of clinical trials testing CDK inhibitors in breast
cancer patients (for example, “Maximum Tolerated
Dose (MTD) of Liposomal Doxorubicin in Combina-
tion With Seliciclib for Patients With Metastatic Triple
Negative Breast Cancer” trial; http://clinicaltrial.gov
identifier NCT01333423) are warranted.
Conclusion
Here we have demonstrated that CCNE1 is a driver of
the 19q12 amplicon and that cancer cells harbouring
CCNE1 gene amplification display an increased sensitiv-
ity to CDK2 RNAi-mediated silencing and chemical
inhibition. It should be noted, however, that CCNE1 was
shown to be amplified only in a subset of breast cancers
harbouring 19q12 amplification. siRNA silencing of all
genes mapping to the 19q12 amplicon revealed the exis-
tence of genes other than CCNE1 whose expression is
selectively required for the survival of cancer cells har-
bouring amplification of this locus. Our results suggest
that drivers other than CCNE1 may exist in the 19q12
amplicon.
Additional material
Additional file 1: Table S1. Phenotypic characteristics of primary breast
tumours analysed by microarray-based comparative genomic
hybridisation. aCGH results previously reported, Natrajan et al. [9].,
Hungermann et al. [30], and Turner et al. [19]. Histological grade assessed
by the modified Scarff-Bloom-Richardson system [32].
Additional file 2: Table S2. Details of the 56 breast cancer cell lines
subjected to microarray-based comparative genomic hybridisation. ER
status, HER2 gene amplification status and p53 protein levels and
mutational status (adapted from Neve et. al. [38], Arriola et al. [20] and
[69] *p53 mRNA levels derived from Mackay et al. [16]. p53 protein levels
and mutational status (obtained from COSMIC [70] and Neve et al. [38]).
“Positive”, detectable protein expression; MUT, mutant; “Negative”, no
detectable protein expression; WT, wild-type.
Additional file 3: Figure S1. Correlation of aCGH smoothed
Log2ratios and FISH. Microarray-CGH chromosome 19 plots illustrating
the patterns of 19q12 amplification in two primary breast cancers (bright
green, circular binary segmentation (cbs)-smoothed Log2 ratio > 0.45),
copy number gain in two primary breast cancers (green, circular binary
segmentation (cbs)-smoothed Log2 ratio > 0.08 to ≤ 0.45 and no copy
number change in two primary breast cancers (black, circular binary
segmentation (cbs)-smoothed Log2 ratio > -0.08 to < 0.08). Log2 ratios
(x-axis) are plotted against BAC position (y-axis). Red: loss, green: gain,
bright green: amplification, purple line: smoothed cbs ratios; amp: 19q12
amplified, gain: 19q12 copy number gain, no change: 19q12 no copy
number change. Fluorescence in situ hybridisation (FISH) confirmation of
19q12 copy number status with a biotin-labelled BAC probe (RP11-
327I05, mapping to 30.10 to 30.25 Mb, red). Top two cases show
amplification with > 5 copies per nucleus, middle two cases low level
gain with three to five copies per nucleus, and bottom two cases no
copy number change with two copies per nucleus.
Additional file 4: Figure S2. Effect of RNA interference gene silencing
on cell cycle profiles. Cell cycle profiles of cancer cells harbouring 19q12
amplification (that is, MDA-MB-157 and HCC1569) or lacking amplification
of this locus (MDA-MB-231, JIMT1, ZR75.1 and BT474) after RNAi silencing
of POP4, PLEKHF1 and TSHZ3. Note the slight increase in the fraction of
subG1 in amplified cells, but no difference in the proportion of G1 or S/
G2 between cell lines with or without amplification at 19q12.
Additional file 5: Figure S3. CCNE1 gene silencing confers resistance to
conventional chemotherapy agents. (A) Dose response curves following
treatment with paclitaxel after CCNE1 silencing using short hairpin RNAs
in cancer cells harbouring CCNE1 gene amplification (that is, MDA-MB-
157 and HCC1569) or lacking amplification at this locus (that is, MDA-MB-
231 and ZR75.1). (B) Dose response curves after CCNE1 silencing to i)
doxorubicin, ii) cisplatin and iii) paclitaxel in cancer cells harbouring
(MDA-MB-157) or lacking (ZR75.1) 19q12 amplification.
Abbreviations
aCGH: microarray comparative genomic hybridisation; BAC: Bacterial Artificial
Chromosome; CDK2: cyclin-dependent kinase 2; CHORI: Children’s Hospital
Oakland Research Institute; BACE: Breakthrough Array CGH Expression; cbs:
circular binary segmentation; ER: oestrogen receptor; FACS: fluorescence-
activated cell sorting; FISH: fluorescence in situ hybridisation; MTD: Maximum
Tolerated Dose; NKI: Netherlands Cancer Institute; PR: progesterone receptor;
Mb: megabase(s); qRT-PCR: Real-time quantitative reverse transcriptase PCR;
siRNA: small interfering RNA.
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